Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Vaccination against SIV infection with subunit proteins vs inactivated virus.
Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 118. Unique Identifier : AIDSLINE PRIM10/93200959 Israel ZR; Maul DH; Bruck C; Thiriart C; Mullins JI; Fultz PN; Burny A; Hoover EA; Department of Pathology, Colorado State University, Fort Collins; 80523.
Abstract:
The goal of this work was to evaluate the efficacy of immunization with either env or env+gag proteins vs. whole inactivated virus prepared from SIVmac251 clone BK28. Twenty three juvenile M. mulatta were placed into 6 vaccine groups of 3 macaques each as follows: (1) WIV boosts after priming with live intradermal VV gag/pol/env; (2) WIV only; (3) gag+env proteins with VV gag+env priming; (4) gag+env; (5) env with VV env priming; (6) env. Two control groups of 3 and 2 macaques were immunized with either adjuvant (threonyl MDP in SAF-1) alone or wild type VV alone. The animals were immunized 4 times at 0, 1.5, 3, and 12 months and challenged 3 weeks later. The exception to this schedule was group 2 (WIV), which received 3 immunizations at 0, 1, and 6 months with challenge 3 weeks later. All the macaques were challenged with 20 AID50 of BK28 pre-titered in naive rhesus macaques. Vaccination elicited high titers of BK28-syncytium-inhibiting (SI) and anti-env antibodies (Ab) in all groups. Only animals in groups 1 through 4 produced anti-gag Ab. Only animals in groups 1 and 2 (WIV) produced anti-HuT78 cell Ab. In the early (2 to 6 week) period after BK28 challenge, virus was isolated from at least one PBMC co-culture in 19 of 23 animals, including all vaccine groups. By 21 weeks post challenge, however, virus isolations (VI) remained positive in 4 of 5 control animals, 1 of 6 WIV animals, 0 of 6 animals env or VVenv animals, and 3 of 6 gag+env or VVgag+env animals. PBMC from 7 of the 12 VI-negative macaques were also negative by PCR. Decreasing SIV SI, gag, and env Ab titers were present in 11 of the 12 VI-negative macaques. We conclude that vaccination with both WIV and env glycoprotein (with or without VV priming) imparts significant resistance against homologous SIVmacBK28 challenge. In addition, this study suggests that vaccination acts to substantially suppress the level of virus expression in animals in which sterilizing immunity has not been achieved.
Keywords: Animal Comparative Study Gene Products, env/*IMMUNOLOGY Gene Products, gag/*GENETICS Immunization Immunization Schedule Macaca mulatta Macromolecular Systems Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL *SIV Vaccines, Inactivated/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Viral Vaccines/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE ABSTRACT 930630
M9361061
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
